Search Results 51-60 of 9667 for TNF

1. Crohn's Disease Clinical Trials - Mayo Clinic Research

   ... tumor necrosis factor (TNF-IR). Participants who enroll on the basis of refractory or intolerance to CS and/or IS may have been previously exposed to anti ...

2. Projects - Liver Pathobiology Lab: Gregory J. Gores - Mayo Clinic Research

   Cholestatic liver injury. The overall objective of this proposal is to examine the hypothesis that ductular reactive cells induce macrophage TNF-related ...

3. AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis - Mayo Clinic

   A maximum of approximately 50% of subjects with any prior anti-TNF agent use will be allowed in the study. At the end of the double blind period, subjects ...

4. Overview - Human Immunodeficiency Virus Lab: Andrew D. Badley - Mayo Clinic Research

   TNF-related apoptosis-inducing ligand (TRAIL) short, an antagonistic TRAIL splice variant. Casp8p41, a fragment of caspase-8 that is produced through the ...

5. AMG 181 in Subjects with Moderate to Severe Crohn's Disease - Mayo Clinic

   A maximum of approximately 80% of subjects with any prior anti-TNF agent use will be allowed in the study. At the end of the double blind period, subjects ...

6. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

   ... tumor necrosis factor (TNF-IR). Participants who enroll on the basis of refractory or intolerance to CS and/or IS may have been previously exposed to anti ...

7. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   ... TNF-alpha therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

8. The effects of bed rest on cardiac and muscle-pump baroreflexes - Mayo Clinic

   ... tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), total tau protein (t-Tau), insulin-like growth factor 1 (IGF-1), brain-derived neurotrophic ...

9. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Anti-TNF naïve; or Has initiated only one anti-TNF treatment including participants with inadequate response to the anti-TNF; Note: participants who ...

10. Tofacitinib is first oral medication approved for use in treating moderate to severe ulcerative colitis - Mayo Clinic

    "It also appears to be efficacious in both the anti-TNF-exposed and anti-TNF-naive populations. So this will be a welcome addition to our armamentarium of ...